RESUMO
This document has been developed by the Lazio regional chapters of two scientific associations, the Italian National Association of Hospital Cardiologists (ANMCO) and the Italian Society of Emergency Medicine (SIMEU), whose members are actively involved in the everyday management of Acute Coronary Syndromes (ACS). The document is aimed at providing a specific, practical, evidence-based guideline for the effective management of antithrombotic treatment (antiplatelet and anticoagulant) in the complex and ever changing scenario of ACS. The document employs a synthetic approach which considers two main issues: the actual operative context of treatment delivery and the general management strategy.
Assuntos
Síndrome Coronariana Aguda/tratamento farmacológico , Cardiologia , Consenso , Serviço Hospitalar de Emergência/normas , Fibrinolíticos/uso terapêutico , Guias de Prática Clínica como Assunto , Sociedades Médicas , Medicina de Emergência , Humanos , Itália , Admissão do PacienteRESUMO
AIMS: The aim of this study was to investigate the relationship between ventriculo-arterial coupling (VAC) and in-hospital outcomes and to assess the prognostic value of VAC in critically ill patients. METHODS AND RESULTS: A total of 329 consecutive patients (mean age 66,7 ± 15.5 years, 66.9% male) admitted to the intensive cardiac care unit of the Sandro Pertini Hospital, Rome (Italy) between January 2019 and December 2019, were included in the study. All patients underwent blood pressure measurement and non-invasive, echocardiography-derived estimates of left ventricular end-systolic elastance (Ees), arterial elastance (Ea) and VAC in a single-beat determination using the iElastance© application. In-hospital events related to acute heart failure and hypoperfusion were recorded and need for invasive ventilation, intra-aortic balloon pump, renal replacement therapy and death were considered as composite. Overall, 39 patients (11,8%) experienced in-hospital complications (group C), and 290 (88,2%) did not (group NoC). Ea and VAC were found to be significantly higher in group C than in group NoC, and a trend toward decreased Ees was observed in group C. VAC was a strong and independent predictor of in-hospital clinical outcome both at univariable and multivariable analysis adjusted for comorbidities [OR (95% CI): 1.868 (1.141-3.059); P = 0.013] and hemodynamic parameters [OR (95% CI): 1674 (1018-2755); P = 0.042]. CONCLUSION: VAC might be an additional non-invasive prognosticator of outcome in critically ill patients.
Assuntos
Insuficiência Cardíaca , Coração Auxiliar , Ecocardiografia , Feminino , Ventrículos do Coração/diagnóstico por imagem , Humanos , Masculino , Prognóstico , Volume SistólicoRESUMO
Here, we report the case of a young patient admitted to the emergency department because of abdominal pain. Computed tomography revealed a mass within her right heart. Through serial multimodality imaging testing, including computed tomography, three-dimensional (2D)- and three-dimensional echocardiography, as well as cardiac magnetic resonance, the diagnosis of cardiac involvement in the course of Echinococcus granulosus infection was hypothesized.
RESUMO
BACKGROUND: Different tools and devices are effective to reduce operator radiation exposure at thorax level during percutaneous coronary procedures, but the operator radiation dose received at pelvic region still remains high. Our aim was to evaluate the efficacy of under-the-table adjunctive shields to reduce operator radiation exposure during percutaneous coronary procedures Methods and Results: The EXTRA-RAD study (Extended Protective Shield Under Table to Reduce Operator Radiation Dose in Percutaneous Coronary Procedures) is a prospective, single-center, randomized study. Patients who underwent transradial coronary procedures were randomized into 2 groups: group 1 (standard arrangement) and group 2 (adjunctive anti-rx shield under the angiographic table). In group 2, a further randomization was performed to compare 2 different under-the-table shields (a small curtain and a drape). A total of 205 procedures (122 diagnostic coronary angiographies and 83 percutaneous coronary interventions) performed in 157 patients by 4 different operators were included without significant differences in clinical and procedural characteristics between groups. The use of adjunctive shields was associated with lower radiation dose compared with no shield at pelvic region (42 µSv [14-98] in group 1, 13 µSv [5-27] in group 2; P<0.0001) and also at thorax level (4 µSv [1-13] in group 1, 2 µSv [1-4] in group 2; P=0.001). The reduction in dose was observed in all the operators. No significant differences were observed in pelvic dose using the 2 different shields ( P=0.183). CONCLUSIONS: The use of adjunctive anti-rx shields under the angiographic table during transradial coronary procedures is associated with a significant lower radiation dose to operators at pelvic and thorax level. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03259126.
Assuntos
Angiografia Coronária , Exposição Ocupacional/prevenção & controle , Saúde Ocupacional , Mesas Cirúrgicas , Intervenção Coronária Percutânea , Doses de Radiação , Exposição à Radiação/prevenção & controle , Proteção Radiológica/instrumentação , Radiografia Intervencionista , Campos Cirúrgicos , Idoso , Angiografia Coronária/efeitos adversos , Desenho de Equipamento , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Exposição Ocupacional/efeitos adversos , Intervenção Coronária Percutânea/efeitos adversos , Estudos Prospectivos , Exposição à Radiação/efeitos adversos , Radiografia Intervencionista/efeitos adversos , Medição de Risco , Fatores de Risco , Cidade de RomaRESUMO
BACKGROUND: Acute heart failure (AHF) after ST-segment elevation myocardial infarction (STEMI) is usually treated with inotropic support or vasoactive medications. In this study, we aimed at investigating the role of levosimendan on cardiovascular determinants of contractility and afterload in patients with AHF following STEMI treated with percutaneous coronary intervention (PCI). METHODS: Forty-eight consecutive STEMI patients were retrospectively enrolled. Non-invasive assessment of left ventricular elastance (Ees) and arterial elastance (Ea) and their relationship, ventriculo-arterial coupling (VAC) was performed before and after levosimendan infusion. RESULTS: After infusion of levosimendan a significant increase in SV was detected in all patients (from 48⯱â¯17 to 60⯱â¯21â¯ml, pâ¯<â¯0.001). VAC slightly decreased from 1.74⯱â¯0.8 to 1.66⯱â¯0.7 (pâ¯=â¯NS) as a result of a profound reduction in arterial elastance (Ea 2.34⯱â¯1.09 to 1.74⯱â¯0.5â¯mmâ¯Hg/ml, pâ¯<â¯0.001) and in ventricular elastance (Ees 1.57⯱â¯0.12 to 1.24⯱â¯0.09â¯mmâ¯Hg/ml, pâ¯=â¯0.021). Ejection fraction (EF) (from 0.29⯱â¯0.1 to 0.32⯱â¯0.1, pâ¯<â¯0.01) and WMSI, (from 2.16⯱â¯0.47 to 2.05⯱â¯0.54, pâ¯<â¯0.05) also, significantly improved. Finally, baseline VAC was able to predict the use of norepinephrine (NE) and early and one-year mortality of patients treated. CONCLUSION: In STEMI patients with AHF the use of levosimendan significantly increases stroke volume after 24-hour treatment through Ea reduction. Baseline VAC seemed to predict early and late mortality and early and prolonged use of NE, however, this needs to be tested in larger series of patients and multivariate adjustments for other prognostic predictors.
Assuntos
Aorta Torácica/fisiopatologia , Ventrículos do Coração/fisiopatologia , Contração Miocárdica/efeitos dos fármacos , Infarto do Miocárdio com Supradesnível do Segmento ST/diagnóstico , Simendana/administração & dosagem , Volume Sistólico/efeitos dos fármacos , Disfunção Ventricular Esquerda/diagnóstico , Idoso , Aorta Torácica/diagnóstico por imagem , Cardiotônicos/administração & dosagem , Ecocardiografia Doppler , Elasticidade , Feminino , Seguimentos , Ventrículos do Coração/diagnóstico por imagem , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Intervenção Coronária Percutânea , Prognóstico , Estudos Retrospectivos , Infarto do Miocárdio com Supradesnível do Segmento ST/complicações , Infarto do Miocárdio com Supradesnível do Segmento ST/terapia , Disfunção Ventricular Esquerda/etiologia , Disfunção Ventricular Esquerda/fisiopatologiaRESUMO
BACKGROUND: The use of adjunctive protective drapes placed on the patient protects the operating physician from scatter radiation during percutaneous coronary procedures (PCP). No data are available on the effect of these drapes for staff members' radio-protection. PURPOSE: To evaluate staff radiation exposure during PCP and the effect of adjunctive protective drapes on dose reduction. METHODS: The RADIANT study (NCT01974453) is a prospective, observational study evaluating operator radiation exposure during PCP using electronic dosimeter. In a sub-group of procedures all the staff members (II operator, nurse circulator and technologist) were also equipped with a dedicated electronic dosimeter. RESULTS: From a total of 2028 procedures included in the RADIANT study, staff members' doses were available for 122 procedures (67 coronarography and 55 percutaneous coronary interventions). Median fluoroscopy time was 306â¯s (Interquartile range 155-526â¯s) and the dose area product (DAP) was 18.0â¯Gy*cm2 (10-35.5â¯Gy*cm2). The radiation exposure was highest for the operating physician (6.7⯵Sv) and progressively lower for the nurse circulator (1.8⯵Sv), the II operator (1⯵Sv) and the technologist (0.7⯵Sv, pâ¯<â¯0.001). Protective pelvic drapes were used in 43 procedures and associated with a lower radiation exposure for all staff members (14⯵Sv vs 2.2⯵Sv for operating physician, pâ¯<â¯0.001, 1.7⯵Sv vs 0.49⯵Sv for II operator, pâ¯<â¯0.001, 2.16⯵Sv vs 0.93⯵Sv for nurse circulator, pâ¯=â¯0.02 and 0.85⯵Sv vs 0.39⯵Sv for technologist, pâ¯=â¯0.01). CONCLUSIONS: The use of adjunctive protective drapes is effective in reducing radiation protection for all staff members during PCP.
Assuntos
Pessoal de Saúde , Exposição Ocupacional/prevenção & controle , Saúde Ocupacional , Intervenção Coronária Percutânea , Doses de Radiação , Exposição à Radiação/prevenção & controle , Proteção Radiológica/instrumentação , Radiografia Intervencionista , Campos Cirúrgicos , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recursos Humanos de Enfermagem , Exposição Ocupacional/efeitos adversos , Auxiliares de Cirurgia , Intervenção Coronária Percutânea/efeitos adversos , Médicos , Estudos Prospectivos , Fatores de Proteção , Exposição à Radiação/efeitos adversos , Radiografia Intervencionista/efeitos adversos , Medição de Risco , Fatores de Risco , Espalhamento de Radiação , Fatores de TempoRESUMO
Cardiogenic shock (CS) is a rare disease that needs a rapid and multiparameter diagnosis and a timely, aggressive and multidisciplinary goal-oriented treatment. Recently published epidemiological studies and registries underline how SC represents an infrequent clinical entity still burdened by high mortality rates, substantially unchanged over the years. Currently, only few patients with CS are treated with circulatory assistance in dedicated centers. Some consensus documents and expert recommendations emphasize the importance of early diagnosis of CS, immediate pharmacological support, and treatment of precipitating causes, and stress the need for hospitalization in high-volume intensive care centers. The aim of this review is to show the instructions for the creation of a SC network, emphasizing the necessary elements, in agreement with available resources and existing health regulations for giving the same care opportunities to all the patients.
Assuntos
Doenças Raras/diagnóstico , Doenças Raras/terapia , Choque Cardiogênico/diagnóstico , Choque Cardiogênico/terapia , Lista de Checagem , Árvores de Decisões , Humanos , Encaminhamento e ConsultaRESUMO
BACKGROUND: An early invasive strategy (EIS) has been shown to yield a better clinical outcome than an early conservative strategy (ECS) in patients with non-ST-elevation acute coronary syndromes (NSTEACSs), particularly in those at higher risk according to the GRACE risk score. However, findings of the clinical trials have not been confirmed in registries. OBJECTIVE: To investigate the outcome of patients with NSTEACS treated according to an EIS or a ECS in a real-world all-comers outcome research study. METHODS: The primary hypothesis of the study was the non-inferiority of an ECS in comparison with an EIS as to a combined primary end-point of death, non-fatal myocardial infarction and hospital readmission for acute coronary syndromes at one year. Participating centres were divided into two groups: those with a pre-specified routine EIS and those with a pre-specified routine ECS. Two statistical analyses were performed: a) an 'intention to treat' analysis: all patients were considered to be treated according to the pre-specified routine strategy of that centre; b) a 'per protocol' analysis: patients were analysed according to the actual treatment applied. Cox model including propensity score correction was applied for all analyses. RESULTS: The intention to treat analysis showed an equivalence between EIS and ECS (11.4% vs. 11.1%) with regard to the primary end-point incidence at one year. In the three subgroups of patients according to the GRACE risk score (⩽ 108, 109-140, > 140), EIS and ECS confirmed their equivalence (5.3% vs. 3.9%, 8.4% vs. 7.6%, and 20.3% vs. 20.9%, respectively). When the per protocol analysis was applied, a reduction of the primary end-point at one year with EIS vs. ECS was demonstrated (6.2% vs. 15.3%, p=0.021); analysis of the subgroups according to the GRACE risk score numerically confirmed these data (3.1% vs. 6.5%, 5.1% vs. 10.0%, and 10.8% vs. 24.5%, respectively). CONCLUSIONS: In a real-life registry of all-comers NSTEACS patients, ECS was non-inferior to EIS; however, when EIS was applied according to clinical judgement, a reduction of clinical events at one year was demonstrated.
Assuntos
Síndrome Coronariana Aguda/terapia , Tratamento Conservador/normas , Eletrocardiografia , Análise de Intenção de Tratamento/métodos , Revascularização Miocárdica/normas , Guias de Prática Clínica como Assunto , Tempo para o Tratamento , Síndrome Coronariana Aguda/diagnóstico , Síndrome Coronariana Aguda/fisiopatologia , Idoso , Feminino , Humanos , MasculinoRESUMO
Coronary artery disease in octogenarians is often diffuse and difficult to manage due to concomitant peripheral vascular disease. The authors describe a case in which an unprotected left main coronary artery was successfully treated by transradial stenting in a patient with severe angina and Leriche syndrome.
Assuntos
Angina Instável/epidemiologia , Angina Instável/terapia , Síndrome de Leriche/epidemiologia , Stents , Idoso de 80 Anos ou mais , Estenose das Carótidas/epidemiologia , Comorbidade , Angiografia Coronária , Reestenose Coronária/diagnóstico por imagem , Reestenose Coronária/epidemiologia , Reestenose Coronária/terapia , Estenose Coronária/diagnóstico por imagem , Eletrocardiografia , Humanos , RetratamentoAssuntos
Aneurisma Coronário , Intervenção Coronária Percutânea , Infarto do Miocárdio com Supradesnível do Segmento ST , Aneurisma Coronário/complicações , Aneurisma Coronário/diagnóstico por imagem , Angiografia Coronária , Eletrocardiografia , Humanos , Pirazóis/efeitos adversos , Piridonas , Infarto do Miocárdio com Supradesnível do Segmento ST/diagnóstico por imagem , Resultado do TratamentoRESUMO
Little is known about the efficacy and medium-term outcomes of primary percutaneous coronary intervention (PCI) in very old patients. We evaluated in-hospital and 6-month outcomes in a retrospective cohort of nonagenarian patients presenting at our hospital with ST-segment elevation myocardial infarction (STEMI) and treated by primary PCI from January 2003 to May 2012. During this period, primary PCI was performed in 1598 consecutive patients; twenty-seven patients (age, 92.5 ± 2.5 years) were enrolled in the study. Four patients (15%) were in advanced Killip class at presentation. STEMI location was anterior in 44%. Patients received aspirin, 300 mg clopidogrel loading dose, and heparin. Abciximab was given to 41% of patients. Coronary angiography showed multivessel disease in 52% of patients. Pain-to-balloon and door-to-balloon times were 375.0 ± 410.2 minutes and 107.3 ± 47.6 minutes, respectively. Intra-aortic balloon pump was implanted in 1 patient. An average of 1.3 ± 0.7 stents (95% bare-metal stents) were implanted per patient. Procedural success rate, defined as Thrombolysis in Myocardial Infarction (TIMI) flow grade ≥ 2 and residual stenosis <20%, was 89%. Hospital mortality was 18.5%. TIMI major bleeding and acute renal failure, defined as an absolute increase of 0.5 mg/dL serum creatinine, occurred in 7% and 22% of patients, respectively. Overall 6-month survival rate was 67%. Our data suggest that primary PCI can be performed in nonagenarian patients with high success rate and with an acceptable bleeding risk, even when aggressive antithrombotic drugs, such as glycoprotein IIb/IIIa inhibitors, are given.
Assuntos
Eletrocardiografia , Infarto do Miocárdio/terapia , Intervenção Coronária Percutânea , Sistema de Registros , Stents , Fatores Etários , Idoso de 80 Anos ou mais , Estudos de Coortes , Angiografia Coronária , Feminino , Seguimentos , Mortalidade Hospitalar , Humanos , Estimativa de Kaplan-Meier , Estudos Longitudinais , Masculino , Infarto do Miocárdio/mortalidade , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do TratamentoRESUMO
We sought to assess the clinical efficacy of thrombus aspiration during primary percutaneous coronary interventions (PCI) in patients presenting with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS). We retrospectively selected 44 patients with CS out of a population of 842 STEMI patients treated with primary PCI at our Hospital between March 2003 and October 2007. Twenty-six patients died during hospital stay (59.1%, Group 1), whereas the remaining 18 were discharged (40.9%, Group 2). Post-procedural ST-segment resolution was greater (68.0%+/-35.6 vs. 43.0%+/-35.0; p=0.06) and in-hospital mortality was significantly lower (21.4% vs 76.6%; p<0.01) in patients treated by TA as compared to patients undergoing standard PCI. At multivariate logistic regression analysis, TA was the only variable independently associated with survival.
Assuntos
Angioplastia Coronária com Balão , Trombose Coronária/cirurgia , Infarto do Miocárdio/complicações , Choque Cardiogênico/complicações , Trombectomia , Idoso , Idoso de 80 Anos ou mais , Trombose Coronária/complicações , Feminino , Mortalidade Hospitalar , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/mortalidade , Estudos Retrospectivos , Choque Cardiogênico/mortalidade , Choque Cardiogênico/terapiaRESUMO
MicroRNAs are key, recently discovered, regulators of gene expression. They are involved in many physiological cellular pathways so it is not surprising that an altered microRNA expression pattern can be involved in the pathogenesis of many disease states. The possibility to manipulate microRNAs to obtain a therapeutical effect is very attractive since they represent specific targets in a particular cellular pathway and because it is quite easy to synthesize short oligonucleotides with the ability to interfere with microRNA mechanism of action. The main problem for microRNA-based therapy is represented by delivery. In the last two years many studies have underlined the involvement of microRNAs in many aspects of ischemic heart disease, the leading cause of morbidity and mortality in the Western World. MiR-29 is involved in fibrotic reaction after myocardial infarction while miR-21 may exert a fundamental role in post-angioplasty restenosis. MiR-208 is involved in the shift toward a fetal gene expression pattern in contractile proteins in heart failure. MiR-1 influences susceptibility to cardiac arrhythmias after myocardial infarction. This review will focus on microRNAs involvement in multiple aspects of ischemic heart disease and on their promising novel therapeutic applications including some recent patents.
Assuntos
MicroRNAs/fisiologia , Isquemia Miocárdica/metabolismo , Angioplastia Coronária com Balão , Animais , Arritmias Cardíacas/genética , Arritmias Cardíacas/metabolismo , Arritmias Cardíacas/terapia , Inativação Gênica , Terapia Genética , Humanos , MicroRNAs/biossíntese , MicroRNAs/genética , Infarto do Miocárdio/genética , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/terapia , Isquemia Miocárdica/genética , Isquemia Miocárdica/terapia , RNA Interferente Pequeno/uso terapêuticoRESUMO
A 68-year-old woman affected by sick sinus syndrome was implanted with a dual-chamber pacemaker provided by home monitoring technology. After discharge, an increase in ventricular threshold and a high variability of R wave measurements were detected early by the home monitoring system. Manual tests confirmed the presence of pacing and sensing failure and a normal ventricular impedance. The pacing lead integrity and a stable position of the lead tip in right ventricular apex were assessed by chest X-ray. A diagnosis of microdislodgement was made. After a second procedure for ventricular lead repositioning, no further malfunctions were detected.
Assuntos
Frequência Cardíaca , Marca-Passo Artificial , Telemetria , Idoso , Eletrocardiografia , Eletrodos Implantados , Falha de Equipamento , Feminino , Humanos , Síndrome do Nó Sinusal/terapiaRESUMO
BACKGROUND: Optimal treatment strategy of patients with ST elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD) undergoing primary angioplasty is still unclear. Percutaneous coronary intervention (PCI) of non-culprit vessels simultaneously or soon after primary angioplasty is feasible and safe, but available data failed to consistently show a benefit in long-term clinical outcomes. METHODS: We retrospectively compared in-hospital and long-term outcomes for patients with STEMI and multivessel CAD treated by primary angioplasty with (Group 1, n=64) or without (Group 2, n=46) early, staged PCI of other angiographically significant coronary lesions. In-hospital major adverse cardiovascular events (MACE) were defined as a composite of death, periprocedural myocardial infarction after staged, elective PCI, stroke, stent thrombosis, major bleeding, and vascular complications. MACE at follow-up were defined as a composite of death, stroke, stent thrombosis, any coronary revascularization, and re-hospitalization for acute coronary syndrome. RESULTS: Group 1 patients underwent staged PCI 5.9 +/- 3.5 days after primary angioplasty. The mean length of follow-up was 13 months (392 +/- 236 days). The incidence of in-hospital MACE was 20.3% in Group 1 and 10.8% in Group 2 (P=0.186); the incidence of out of hospital MACE was 9.3% in Group 1 and 23.9% in Group 2 (P=0.037). In Group 1 in-hospital MACE were driven by periprocedural myocardial infarction after the elective procedure, which occurred in 15.6% of patients. CONCLUSIONS: Our data show that multivessel, staged PCI in STEMI patients is associated with a low incidence of adverse events at follow-up but with a higher incidence of in-hospital MACE, mainly driven by periprocedural myocardial infarction during the elective procedure.
Assuntos
Angioplastia com Balão/efeitos adversos , Doença da Artéria Coronariana/patologia , Vasos Coronários/patologia , Infarto do Miocárdio/complicações , Resultado do Tratamento , Idoso , Angioplastia Coronária com Balão/efeitos adversos , Doença da Artéria Coronariana/fisiopatologia , Determinação de Ponto Final , Feminino , Humanos , Incidência , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/fisiopatologia , Infarto do Miocárdio/terapia , Estudos RetrospectivosRESUMO
We describe the case of a 64-year-old patient with glucose-6-phosphate dehydrogenase deficiency who was referred to our hospital because of an acute inferior myocardial infarction.Given the possible risk of acute haemolytic anaemia, aspirin was not given in the acute phase, and the patient was successfully treated by balloon angioplasty of the right coronary artery.After functional and genetic testing showing the presence of the Mediterranean mutation, known to be a class II variant, the patient received oral daily aspirin (100 mg) under strict monitoring in order to promptly detect any sign of haemolysis. After 4 days, a complex percutaneous coronary intervention with an implantation of two drug-eluting stents was successfully performed on the left coronary artery. After 3 months, the patient is free from adverse events.Glucose-6-phosphate dehydrogenase deficiency is commonly considered a contraindication to aspirin intake; however, this case shows that aspirin at low, antiplatelet dosage is well tolerated and should not be denied to patients with ischaemic heart disease and complex coronary anatomy.
Assuntos
Anemia Hemolítica/induzido quimicamente , Angioplastia Coronária com Balão/instrumentação , Aspirina/efeitos adversos , Stents Farmacológicos , Favismo/complicações , Infarto do Miocárdio/terapia , Inibidores da Agregação Plaquetária/efeitos adversos , Administração Oral , Anemia Hemolítica/genética , Angioplastia Coronária com Balão/efeitos adversos , Aspirina/administração & dosagem , Angiografia Coronária , Favismo/enzimologia , Favismo/genética , Glucosefosfato Desidrogenase/genética , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Infarto do Miocárdio/complicações , Infarto do Miocárdio/diagnóstico por imagem , Infarto do Miocárdio/tratamento farmacológico , Inibidores da Agregação Plaquetária/administração & dosagem , Medição de Risco , Resultado do TratamentoRESUMO
The tako-tsubo syndrome (transient left ventricular apical ballooning with normal coronary arteries), initially described in Japanese patients, is now being increasingly observed worldwide and should be considered in the differential diagnosis of acute coronary syndromes. Angina-like chest pain, electrocardiographic changes and an increase in myocardial markers are often present, as well as history of acute stressful events preceding symptom onset. We report the case of an Asiatic woman in whom typical, reversible abnormalities in left ventricular motion were associated with symptomatic junctional bradycardia. Nevertheless, the patient was completely free from angina and excluded acute pain or emotions in the previous weeks. Coronary angiography showed absence of significant disease and left ventricular function was found to be unremarkable 1 month after the acute event. Although infrequent, atypical presentations of tako-tsubo syndrome have occasionally been reported and, in our opinion, they could provide interesting insights into the ill-defined pathophysiology of the disease.
Assuntos
Bradicardia/etiologia , Cardiopatias/complicações , Ventrículos do Coração/patologia , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
Drug-eluting stents, despite being very effective in reducing restenosis after percutaneous coronary interventions, are associated with a low but definite risk of late thrombotic occlusion with adverse clinical events. To date, the incidence and overall risk of late thrombosis of drug-eluting stents after primary percutaneous coronary interventions for ST-elevation myocardial infarction are not well defined because of the relative paucity of evidence-based data. We report the case of an angiographically confirmed paclitaxel-eluting stent thrombosis, occurring 20 months after successful primary percutaneous coronary intervention in a 41-year-old woman. To the best of our knowledge, this is the most delayed case of paclitaxel-eluting stent thrombosis described so far.